Pharmacogenomics Testing for Overmedication
What You Need to Know Before You Apply
What is the purpose of this trial?
The trial aims to determine if a special DNA test can help doctors select better medications and doses for older adults. It focuses on individuals taking five or more medications who visit a Geisinger 65 Forward clinic. Some participants will receive a multigene pharmacogenomics test, which uses DNA to guide medication choices, while others will continue with their regular care. Participants who have had a liver or certain stem cell transplants, or who have participated in another genetics study, are not eligible. The goal is to reduce medication problems and healthcare costs for participants. As an unphased trial, this study offers participants the chance to contribute to innovative research that could enhance medication management for older adults.
Do I need to stop my current medications for the trial?
The trial protocol does not specify whether you need to stop your current medications. However, since the study involves testing the impact of DNA testing on medication selection and dosing, it's possible that changes to your medication regimen could occur.
What prior data suggests that this pharmacogenomics test is safe?
Previous studies have shown promise in testing multiple genes through pharmacogenomics (a DNA test that examines several genes) for making medications safer and more effective. Research indicates that this type of testing is generally well-tolerated. For example, one study found that it improves medication use in primary care, helping doctors select the right drugs and doses for patients.
No reports of serious side effects or adverse events have been linked to the multigene pharmacogenomics test itself. The test usually involves a simple blood draw, a common and low-risk procedure. So far, evidence suggests this testing is safe for study participants.12345Why are researchers excited about this trial?
Researchers are excited about pharmacogenomics testing for overmedication because it offers a personalized approach to medication management. Unlike the standard practice, which often involves trial and error with medications, this test uses a patient's genetic information to predict how they will respond to different drugs. This means medications can be tailored specifically to the individual's genetic makeup, potentially reducing the risk of overmedication and adverse drug reactions. Additionally, by understanding genetic variations, healthcare providers can make more informed decisions, leading to safer and more effective treatments.
What evidence suggests that this pharmacogenomics test is effective for overmedication?
Research has shown that testing how genes affect medicine response can enhance treatment effectiveness, particularly for older adults. In this trial, participants in the experimental arm will receive a multigene pharmacogenomics test. This test aids doctors in selecting the right medications, potentially reducing healthcare costs and improving treatment outcomes. Testing multiple genes simultaneously, rather than just one, has proven more cost-effective. This approach helps doctors determine the best medicines and doses based on a patient's genetic makeup. By personalizing treatments, patients may experience fewer side effects and achieve better overall results.678910
Who Is on the Research Team?
Ryley Uber, Pharm.D.
Principal Investigator
Geisinger Clinic
Are You a Good Fit for This Trial?
This trial is for older adults who are patients at Geisinger 65 Forward clinics and take five or more medications. It's not open to those who've had liver transplants, stem cell transplants, or were part of the eMERGE pharmacogenomics study.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Randomization
Participants are randomly assigned to either the pharmacogenomics testing group or the standard care group
Pharmacogenomics Testing
Participants in the experimental arm undergo a multigene pharmacogenomics test with results reported in the medical record
Follow-up
Participants are monitored for changes in medication therapy, healthcare utilization, and costs of care
What Are the Treatments Tested in This Trial?
Interventions
- Multigene pharmacogenomics test
Trial Overview
The trial is testing a multigene pharmacogenomics test that examines DNA to guide medication choices and dosages for geriatric patients, aiming to improve healthcare outcomes and reduce costs.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Patients in the experimental arm will be ordered a multigene pharmacogenomics test. This DNA test requires a blood draw, with the results expected to be reported in the medical record approximately 7 to 14 calendar days after the blood draw. These results will be made available to Geisinger healthcare professionals that have a treatment relationship with study participants.
A multigene pharmacogenomics test will not be ordered for patients in this study arm, as is the standard of care.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Geisinger Clinic
Lead Sponsor
Published Research Related to This Trial
Citations
Real-World Impact of Pharmacogenomic Testing on ...
Pharmacogenomic (PGx) testing is one tool that may improve medication outcomes in patients with MDD while reducing associated healthcare costs.
Cost Effectiveness of Pharmacogenetic Testing for Drugs ...
The objective of this study was to evaluate the evidence on cost‐effectiveness of pharmacogenetic (PGx)–guided treatment for drugs with Clinical ...
Cost-Effectiveness of Multigene Pharmacogenetic Testing ...
Multigene testing for Medicare patients post-PCI for ACS has a higher probability of being cost-effective over 24 months and the lifetime compared with single- ...
Cost-Effectiveness of Multigene Pharmacogenomic Testing ...
The pharmacist explained that these PGx test results could be used to guide numerous potential future medication reg- imens as well, including certain ...
Navigating Pharmacogenomic Testing in Practice: Who to Test ...
There is increasing attention on the clinical utility and value of pharmacogenetic (PGx) testing to individualize medication management.
Pharmacogenetic interventions to improve outcomes in ...
Studies involving multi-medicine pharmacogenetics in adults with multimorbidity or polypharmacy, reporting on outcomes derived from relevant core outcome sets, ...
Pre-emptive pharmacogenomics implementation among ...
Aim: Pre-emptive testing of pharmacogenomic (PGx) variations has potential to improve medication safety and effectiveness; however, ...
Abstracts - 2025 - Clinical Pharmacology & Therapeutics
BACKGROUND: Pharmacogenomic (PGx) testing using multi-gene panels (mgPGx) is documented to improve clinical outcomes; however, real-world data ...
Pharmacogenomic testing to support prescribing in primary ...
The application of pharmacogenomics could meaningfully contribute toward medicines optimization within primary care.
Trends in and predictors of patient pharmacogenomic test ...
This study examined patient and provider factors associated with PGx test ordering in a national health care system in which panel-based testing was implemented ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.